Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers

Journal of Rheumatology

Volumn 39, Issue 3, 2012, Pages 568-573

  Iervolino, Salvatore ^a   Di Minno, Matteo Nicola Dario ^a   Peluso, Rosario ^a   Lofrano, Mariana ^a   Russolillo, Anna ^a   Di Minno, Giovanni ^a   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Minimal disease activity; Predictors of response; Psoriatic arthritis; Tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CHOLESTEROL; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; ATOPY; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; INFUSION REACTION; INJECTION SITE REACTION; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RELIABILITY; RITCHIE INDEX; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE;

ADULT; AGE FACTORS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857888495     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110763     Document Type: Article

References (42)

1. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-4. (Pubitemid 30265607)
2. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
3. Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M, et al. Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". J Rheumatol 2003;30:2638-40. (Pubitemid 37549343)
4. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50. (Pubitemid 30262512)
5. Gladman DD, Stafford-Brady F, Chang C-H, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12. (Pubitemid 20213507)
6. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953;249:553-6.
7. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
8. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6. (Pubitemid 28558973)
9. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72. (Pubitemid 27452539)
10. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. TNF-a blockers and carotid intima-media thickness: An emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 2011 Oct 1. [Epub ahead of print]
11. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012;39: [in press].
12. Scarpa R, Altomare G, Marchesoni A, Balato A, Matucci Cerinic A, Lotti T, et al. Psoriatic disease: Concepts and implications. J Eur Acad Dermatol Venereol 2010;24:627-30.
13. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum 2007;56:476-88.
14. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
15. Van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al, for the IMPACT 2 Study Group. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2. Arthritis Rheum 2007;56:2698-707. (Pubitemid 47237288)
16. de Vlam K, Lories RJ. Remission in psoriatic arthritis. Curr Rheumatol Rep 2008;10:297-302.
17. Cantini F, Niccoli L, Nannini C, Cassara' E, Pasquetti P, Olivieri I, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 2008;47:872-6. (Pubitemid 351796376)
18. Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J Rheumatol 2001;28:1045-8. (Pubitemid 32422587)
19. Coates LC, Cook R, Lee K, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-6.
20. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-8. (Pubitemid 44620449)
21. Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology 2000;39:148-55. (Pubitemid 30139347)
22. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-9.
23. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CAE, et al. Remission in psoriatic arthritis: Is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
24. Eder L, Chandran V, Schentag CT, Shen H, Cook RJ, Gladman DD. Time and predictors of response to tumor necrosis factor-a blockers in psoriatic arthritis: An analysis of a longitudinal observation cohort. Rheumatology 2010;49:1361-6.
25. Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 2005;44:390-7. (Pubitemid 40361300)
26. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
27. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009;68:777-83.
28. Di Minno MN, Tufano A, Guida A, Di Capua M, De Gregorio AM, Cerbone AM, et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res 2011;127:193-7.
29. Di Minno MN, Tufano A, Russolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 2010;16:6119-22.
30. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: Differences between tumor necrosis factor-a blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705-12.
31. Gratacos J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007;66:493-7. (Pubitemid 46580470)
32. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
33. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis. The Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
34. Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004;16:350-6. (Pubitemid 38803134)
35. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7. (Pubitemid 41113349)
36. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49-54. (Pubitemid 40288522)
37. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: A preliminary definition. J Rheumatol 2005;32:2016-24. (Pubitemid 41429036)
38. Coates LC, Cook R, Lee K, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-6.
39. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
40. Olivieri I, Mantovani LG, D'Angelo S, Padula A, de Portu S. Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep 2009;11:263-9.
41. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: Results from a single centre. Ann Rheum Dis 2007;66:370-6. (Pubitemid 46579640)
42. Cresswell L, Chandran V, Farewell VT, Gladman DD. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011;70:305-8.